Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 132

Sort by

Sort Order Select

Journal Articles

Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trial

Blood blood.2025030816.

https://doi.org/10.1182/blood.2025030816

Published: 2025

Includes: Supplemental data

Journal Articles

Disease risk but not remission status determines transplant outcomes in AML: long-term outcomes of the ASAP trial

Blood (2025) 146 (19): 2293–2305.

https://doi.org/10.1182/blood.2025028730

Published: 2025

Includes: Supplemental data

Journal Articles

Real-world experience with IDH inhibitors in Acute Myeloid Leukemia: A german multicenter analysis with a focus on differentiation syndrome

Krischan Braitsch, Karin Huber, Andrew Berdel, Lydia Kretschmer, Adrian Gottschlich, Tim Lohmann, Kathrin Rieger, Karsten Spiekermann, Thomas Schroeder, Silke Kapp-Schwoerer, Mareike Verbeek, Florian Bassermann, Hartmut Döhner, Tim Sauer, Christoph Röllig, Jan-Henrik Mikesch, Franziska Westendorf, Lars Fransecky, Katharina S. Götze

Blood (2025) 146 (Supplement 1): 2846.

https://doi.org/10.1182/blood-2025-2846

Published: 2025

Journal Articles

Bleximenib or placebo in combination with standard induction and consolidation therapy followed by maintenance for the treatment of patients with newly diagnosed KMT2A-rearranged or NPM1-mutant Acute Myeloid Leukemia eligible for intensive chemotherapy: A double-blind Phase 3 study (HOVON 181 AML / AMLSG 37-25)

Blood (2025) 146 (Supplement 1): 1654.

https://doi.org/10.1182/blood-2025-1654

Published: 2025

Journal Articles

The addition of a tyrosine kinase inhibitor to intensive chemotherapy significantly improves outcome in de novo BCR::ABL1+ acute myeloid leukemia treated with intensive chemotherapy

Sarah Bertoli, Niklas Landberg, Emilie Bérard, Camille Gondran, Laetitia Largeaud, Véronique De Mas, Pierre-Yves Dumas, Arnaud Pigneux, Audrey Bidet, Sylvain Garciaz, Ludovic Gabellier, Gabrielle Roth-Guepin, Corentin Orvain, Pierre Peterlin, Rudy Birsen, Magda Alexis, Martin Carre, Emmanuelle Tavernier, Marion Boissard Simonet, Chantal Himberlin, Marc Maynadié, Kamel Laribi, Cécile Moluçon-Chabrot, Amine Belhabri, Samy Chraibi, Quentin Cabrera, Delphine Lebon, Emmanuel Raffoux, Thomas Cluzeau, Jean-Baptiste Micol, Mathieu Leclerc, Céline Berthon, Herve Dombret, Gunnar Juliusson, Anna Robelius, Sören Lehmann, Martin Jädersten, Lovisa Wennström, Pau Montesinos, Carmen Botella, Juan Miguel Bergua Burgues, Raimundo Garcia, Josefina Serrano, Mariluz Amigo, Patricia Garcia Ramirez, Claudia Sossa, Juan Manuel Alonso-Dominguez, Hartmut Döhner, Konstanze Döhner, Daniela Späth, Michael Kühn, Claudia Lengerke, Hans-Jörg Tischler, Christoph Röllig, Leo Ruhnke, Christian Thiede, Andreas Burchert, Hubert Serve, Carsten Mueller-Tidow, Claudia Baldus, Jurjen Versluis, Peter Valk, Daniel Kristensen, Anne Stidsholt Roug, Jiri Mayer, Mika Kontro, Pia Ettala, Vladimir Lazarevic, Christian Recher

Blood (2025) 146 (Supplement 1): 991.

https://doi.org/10.1182/blood-2025-991

Published: 2025

Journal Articles

Venetoclax combined with five days of azacitidine for the treatment of previously untreated Acute Myeloid Leukemia (AML): Initial results of the prospective venaza-5S trial

Klaus Metzeler, Jens Przybilla, Anne Weigert, Mathias Hänel, Thomas Illmer, Julia Pross, Alexander Höllein, Martin Schmidt-Hieber, Ullrich Graeven, Tim Sauer, Stefan Neuburger, Katharina S. Götze, Dominic Brauer, Madlen Jentzsch, Christoph Röllig, Dirk Hasenclever, Uwe Platzbecker

Blood (2025) 146 (Supplement 1): 46.

https://doi.org/10.1182/blood-2025-46

Published: 2025

Journal Articles

Oral azacitidine maintenance improved survival for t-AML or AML-MR patients in first remission after CPX-351 and not eligible to HSCT

Caroline Fileni, David Swoboda, Alexander Coltoff, Najla Al Ali, Rami Komrokji, Onyee Chan, Geoffrey Uy, Sarah Bertoli, Alessandro Isidori, Lenaig Le Clech, Mael Heiblig, Ludovic Gabellier, Patrick Lawrence, Lydia Kretschmer, Christoph Röllig, Jeffrey Lancet, Andrew Wei, David Sallman, Thomas Cluzeau

Blood (2025) 146 (Supplement 1): 3441.

https://doi.org/10.1182/blood-2025-3441

Published: 2025

Journal Articles

Camelot-2: A phase 3 randomized, double-blind, placebo-controlled, study of bleximenib, venetoclax and azacitidine for the treatment of participants with newly diagnosed Acute Myeloid Leukemia harboring KMT2A rearrangements or NPM1 mutations, who are ineligible for intensive chemotherapy

Blood (2025) 146 (Supplement 1): 3429.

https://doi.org/10.1182/blood-2025-3429

Published: 2025

Journal Articles

Establishing contemporary benchmarks for Acute Myeloid Leukemia outcomes and measurable residual disease: Real-world data utilization from the ELN-david MRD international working group

Blood (2025) 146 (Supplement 1): 5183.

https://doi.org/10.1182/blood-2025-5183

Published: 2025

Journal Articles

Deep learning predicts IDH1 mutation status in Acute Myeloid Leukemia from bone marrow smear images

Jan-Niklas Eckardt, Ishan Srivastava, Chethan Babu, Sebastian Riechert, Tim Schmittmann, Susann Winter, Martin Schneider, Markus Badstübner, Ann-Kathrin Eisfeld, Haley Roberts, Christoph Röllig, Martin Bornhäuser, Jan Moritz Middeke, Andrew Srisuwananukorn

Blood (2025) 146 (Supplement 1): 2558.

https://doi.org/10.1182/blood-2025-2558

Published: 2025

Journal Articles

Venetoclax in combination with hypomethylating agents in adult patients with newly diagnosed AML with CBFB::MYH11 or RUNX1::RUNX1T1 fusions: Real-world outcomes based on international registry data

Blood (2025) 146 (Supplement 1): 5230.

https://doi.org/10.1182/blood-2025-5230

Published: 2025

Journal Articles

Phase 1b study of bleximenib in combination with venetoclax in Acute Myeloid Leukemia with KMT2A or NPM1 alterations

Jenny O'Nions, Andrew Wei, Jordi Esteve, Ibrahim Aldoss, Ana Alfonso-Pierola, Alicia Allred, Juan Manuel Alonso-Dominguez, Laura Barreyro, Pierre Bories, Nikki Daskalakis, Matteo Della Porta, Hartmut Döhner, Amber D'Souza, James Dugan, Amir Fathi, Pasquale Fedele, Lucille Ferrante, Rachel Kobos, Ana Garrido, Sara Garrido Paniagua, Christina Drenberg Guttke, Emmanuel Gyan, Brett Hiebert, Elias Jabbour, Danielle Trancucci, Naa Sackey, Madlen Jentzsch, Hagop Kantarjian, Marina Konopleva, Jan Krönke, Marie Luise Hütter-Krönke, Christina Loefgren, Oliver Lomas, Valentina Mancini, Daniel Morillo, Kathryn Packman, Cristina Papayannidis, Christian Recher, Christoph Röllig, Olga Salamero, Prathap Nagaraja Shastri, Tim Sauer, Dr. Emma Searle, Natalia Tovar, Nicolas Vallet, Lachlin Vaughan, Paresh Vyas, Uwe Platzbecker, Sylvain Garciaz

Blood (2025) 146 (Supplement 1): 5200.

https://doi.org/10.1182/blood-2025-5200

Published: 2025

Journal Articles

Bleximenib in combination with intensive chemotherapy: A phase 1b study in newly diagnosed Acute Myeloid Leukemia with KMT2A or NPM1 alterations

Hartmut Döhner, Andre Schuh, Christian Recher, Jenny O'Nions, Ibrahim Aldoss, Ana Alfonso-Pierola, Alicia Allred, Juan Manuel Alonso-Dominguez, Laura Barreyro, Pierre Bories, Nikki Daskalakis, Matteo Della Porta, Amber D'Souza, James Dugan, Jordi Esteve, Amir Fathi, Lucille Ferrante, Stan Gaj, Sylvain Garciaz, Ana Garrido, Olga Salamero, Christina Drenberg Guttke, Emmanuel Gyan, Brett Hiebert, Elias Jabbour, Madlen Jentzsch, Hagop Kantarjian, Marina Konopleva, Jan Krönke, Marie Luise Hütter-Krönke, Christina Loefgren, Oliver Lomas, Valentina Mancini, Ioannis Mantzaris, Daniel Morillo, Kathryn Packman, Cristina Papayannidis, Ulrike Philippar, Uwe Platzbecker, Sara Garrido Paniagua, Naa Sackey, Tim Sauer, Dr. Emma Searle, Prathap Nagaraja Shastri, Danielle Trancucci, Natalia Tovar, Nicolas Vallet, Lachlin Vaughan, Paresh Vyas, Andrew Wei, Christoph Röllig

Blood (2025) 146 (Supplement 1): 5199.

https://doi.org/10.1182/blood-2025-5199

Published: 2025

Journal Articles

Single versus double “7+3” induction with 60 versus 90 mg/m2 daunorubicin in newly diagnosed AML: Does it matter for NPM1 MRD?

Blood (2025) 146 (Supplement 1): 5298.

https://doi.org/10.1182/blood-2025-5298

Published: 2025

Journal Articles

Validation of measurable residual disease as a surrogate endpoint in acute myeloid leukemia: A HARMONY Alliance study of European randomized trials

Blood (2025) 146 (Supplement 1): 343.

https://doi.org/10.1182/blood-2025-343

Published: 2025

Journal Articles

Acute myeloid leukemias with UBTF tandem duplications respond to combined BCL-2 and RNA polymerase I inhibition with increased stemness and a quiescent-like state

Patrick Stelmach, Nesrine Aroua, Dawn Lin, Elisa Donato, Ann-Kathrin Eisfeld, Christoph Röllig, Christian Thiede, Andreas Trumpp

Blood (2025) 146 (Supplement 1): 342.

https://doi.org/10.1182/blood-2025-342

Published: 2025

Journal Articles

Large B-cell lymphoma imprints a dysfunctional immune phenotype that persists years after treatment

Blood (2025) 146 (11): 1300–1313.

https://doi.org/10.1182/blood.2024027877

Published: 2025

Includes: Supplemental data

Journal Articles

Magrolimab and the tale of indigestible AML

Christoph Röllig

Blood (2025) 146 (5): 527–528.

https://doi.org/10.1182/blood.2025029850

Published: 2025

Journal Articles

Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations

Blood (2024) 144 (21): 2169–2173.

https://doi.org/10.1182/blood.2024025409

Published: 2024

Journal Articles

HLA-DR Expression on Leukemic Progenitor Cells before Allogeneic Hematopoietic Cell Transplantation Adds Prognostic Value in the Presence of MRD

Maximilian Alexander Rohnert, Jonas Schadt, Michael Kramer, Christoph Röllig, Johannes Schetelig, Friedrich Stölzel, Désirée Kunadt, Jan Moritz Middeke, Lars Thielecke, Friedemann Uschner, Ingmar Glauche, Christian Thiede, Martin Bornhaeuser, Uta Oelschlaegel, Malte von Bonin, Uwe Platzbecker, Claudia D Baldus, Hubert Serve, Carsten Mueller-Tidow

Blood (2024) 144 (Supplement 1): 2948.

https://doi.org/10.1182/blood-2024-194874

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trial

Disease risk but not remission status determines transplant outcomes in AML: long-term outcomes of the ASAP trial

Real-world experience with IDH inhibitors in Acute Myeloid Leukemia: A german multicenter analysis with a focus on differentiation syndrome

The addition of a tyrosine kinase inhibitor to intensive chemotherapy significantly improves outcome in de novo BCR::ABL1+ acute myeloid leukemia treated with intensive chemotherapy

Venetoclax combined with five days of azacitidine for the treatment of previously untreated Acute Myeloid Leukemia (AML): Initial results of the prospective venaza-5S trial

Oral azacitidine maintenance improved survival for t-AML or AML-MR patients in first remission after CPX-351 and not eligible to HSCT

Camelot-2: A phase 3 randomized, double-blind, placebo-controlled, study of bleximenib, venetoclax and azacitidine for the treatment of participants with newly diagnosed Acute Myeloid Leukemia harboring KMT2A rearrangements or NPM1 mutations, who are ineligible for intensive chemotherapy

Establishing contemporary benchmarks for Acute Myeloid Leukemia outcomes and measurable residual disease: Real-world data utilization from the ELN-david MRD international working group

Deep learning predicts IDH1 mutation status in Acute Myeloid Leukemia from bone marrow smear images

Venetoclax in combination with hypomethylating agents in adult patients with newly diagnosed AML with CBFB::MYH11 or RUNX1::RUNX1T1 fusions: Real-world outcomes based on international registry data

Phase 1b study of bleximenib in combination with venetoclax in Acute Myeloid Leukemia with KMT2A or NPM1 alterations

Bleximenib in combination with intensive chemotherapy: A phase 1b study in newly diagnosed Acute Myeloid Leukemia with KMT2A or NPM1 alterations

Single versus double “7+3” induction with 60 versus 90 mg/m2 daunorubicin in newly diagnosed AML: Does it matter for NPM1 MRD?

Validation of measurable residual disease as a surrogate endpoint in acute myeloid leukemia: A HARMONY Alliance study of European randomized trials

Acute myeloid leukemias with UBTF tandem duplications respond to combined BCL-2 and RNA polymerase I inhibition with increased stemness and a quiescent-like state

Large B-cell lymphoma imprints a dysfunctional immune phenotype that persists years after treatment

Magrolimab and the tale of indigestible AML

Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations

HLA-DR Expression on Leukemic Progenitor Cells before Allogeneic Hematopoietic Cell Transplantation Adds Prognostic Value in the Presence of MRD

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only